Stay updated with breaking news from Erasca Mapklamp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer Erasca previously signed...
23% of patients with RAS/MAPK-altered non-CRC solid tumors and 44% with BRAF-driven non-CRC solid tumors responded to single agent ERAS-007 or ERAS-601 ERAS-007 and ERAS-601 had favorable... | September 7, 2022
Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from MD Anderson Cancer Center Company to...
Proof-of-concept data from trial may support addition of ERAS-007 as a treatment option to overcome RAS/MAPK resistance to KRAS G12C inhibitors...